新冠出现变种!A股抗疫概念股集体大涨,口罩股现涨停潮
格隆汇12月22日丨新冠出现变种,A股市场口罩、医疗器械、新冠肺炎检测、疫苗等抗疫概念股集体大涨。口罩股中,泰达股份、道恩股份、搜于特、南卫股份、欣龙控股涨停;医疗器械股中,达安基因涨停;疫苗股中,华兰生物、复星医药等均明显上涨。英国出现新冠病毒新变种毒株,其传播能力比原始毒株高70%。英国政府已于当地时间周六紧急对伦敦等地实施“封城”,并收紧全国防疫措施。截至目前,全世界100多个国家禁止英国航班。中国工程院钟南山院士称,英国出现的变异病毒在病死率等方面是否改变还没有具体内容,对于疫苗的有效性是否影响也没有进一步的证据。下图一为A股市场涨幅居前的前20大概念板块;图二为口罩股表现。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.